This review covers the diverse topic of neuroendocrine neoplasms (NENs), a relatively rare
and heterogeneous tumor type, comprising~ 2% of all malignancies, with a prevalence of< …

Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …

Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options …

PURPOSE Patients with advanced pancreatic neuroendocrine tumors (NETs) have few
treatment options that yield objective responses. Retrospective and small prospective …

Background Somatostatin analogues are commonly used to treat symptoms associated with
hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects …

The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations
for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland …

Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase
inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This …

Background Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), has
shown antitumour activity in patients with advanced pancreatic neuroendocrine tumours. We …

Purpose Everolimus improved median progression-free survival by 6.4 months in patients
with advanced pancreatic neuroendocrine tumors (NET) compared with placebo in the …

Background Neuroendocrine tumors (NETs) are a group of heterogeneous cancers arising
from a variety of anatomic sites. Their incidence has increased in recent years. This study …